Clinical Trial Update: The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium [Phase 3]

View source ↗

Summary

Phase 3 trial comparing umeclidinium/vilanterol 62.5/25 mcg once daily to tiotropium 18 mcg once daily over 12 weeks in COPD patients with ongoing symptoms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Umeclidinium/Vilanterol (umeclidinium/vilanterol)
• tiotropium (tiotropium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2016-02-25